Deutsche Bank Ag\ Akebia Therapeutics, Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 110,385 shares of AKBA stock, worth $203,108. This represents 0.0% of its overall portfolio holdings.

Number of Shares

110,385

Holding current value

$203,108

% of portfolio

0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$0.94 - $1.55 $103,761 - $171,096	110,385 New	110,385 $145,000
Q2 2022 Aug 11, 2022	SELL	$0.32 - $0.67 $34,621 - $72,489	-108,193 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$0.72 - $2.93 $8,089 - $32,921	-11,236 Reduced 9.41%	108,193 $78,000
Q4 2021 Feb 11, 2022	BUY	$2.26 - $3.34 $9,591 - $14,174	4,244 Added 3.68%	119,429 $270,000
Q3 2021 Nov 04, 2021	BUY	$2.35 - $3.88 $12,821 - $21,169	5,456 Added 4.97%	115,185 $332,000
Q2 2021 Aug 11, 2021	SELL	$2.83 - $4.2 $4,213 - $6,253	-1,489 Reduced 1.34%	109,729 $416,000
Q1 2021 May 13, 2021	SELL	$2.92 - $5.06 $26,002 - $45,059	-8,905 Reduced 7.41%	111,218 $375,000
Q4 2020 Feb 16, 2021	SELL	$2.22 - $3.78 $712,626 - $1.21 Million	-321,003 Reduced 72.77%	120,123 $336,000
Q3 2020 Nov 12, 2020	BUY	$2.39 - $13.08 $394,775 - $2.16 Million	165,178 Added 59.86%	441,126 $1.11 Million
Q2 2020 Aug 13, 2020	BUY	$6.67 - $13.58 $260,436 - $530,244	39,046 Added 16.48%	275,948 $3.75 Million
Q1 2020 May 14, 2020	BUY	$4.1 - $10.24 $643,495 - $1.61 Million	156,950 Added 196.31%	236,902 $1.8 Million
Q4 2019 Feb 14, 2020	BUY	$3.16 - $6.73 $106,558 - $226,942	33,721 Added 72.94%	79,952 $504,000
Q3 2019 Nov 14, 2019	SELL	$3.55 - $5.4 $367,077 - $558,370	-103,402 Reduced 69.1%	46,231 $180,000
Q2 2019 Aug 14, 2019	BUY	$4.1 - $8.05 $213,368 - $418,930	52,041 Added 53.33%	149,633 $723,000
Q1 2019 May 15, 2019	SELL	$5.41 - $8.73 $409,412 - $660,660	-75,677 Reduced 43.68%	97,592 $797,000
Q4 2018 Feb 14, 2019	SELL	$5.39 - $9.15 $998,502 - $1.7 Million	-185,251 Reduced 51.67%	173,269 $958,000
Q3 2018 Dec 21, 2021	BUY	$7.44 - $10.65 $749,230 - $1.07 Million	100,703 Added 39.06%	358,520 $3.17 Million
Q3 2018 Nov 14, 2018	BUY	$7.44 - $10.65 $707,707 - $1.01 Million	95,122 Added 58.47%	257,817 $2.27 Million
Q2 2018 Apr 21, 2020	BUY	$9.15 - $11.34 $176,741 - $219,043	19,316 Added 13.47%	162,695 $1.62 Million
Q2 2018 Aug 14, 2018	SELL	$9.15 - $11.34 $2.91 Million - $3.61 Million	-318,066 Reduced 68.93%	143,379 $1.43 Million
Q1 2018 Oct 18, 2019	BUY	$9.53 - $15.68 $380,961 - $626,808	39,975 Added 9.48%	461,445 $4.4 Million
Q1 2018 May 15, 2018	BUY	$9.53 - $15.68 $2.48 Million - $4.07 Million	259,830 Added 160.75%	421,470 $4.02 Million
Q4 2017 Feb 14, 2018	SELL	$14.24 - $19.59 $709,152 - $975,582	-49,800 Reduced 23.55%	161,640 $2.4 Million
Q3 2017 Nov 14, 2017	BUY	$13.06 - $19.67 $2.76 Million - $4.16 Million	211,440	211,440 $4.16 Million

Others Institutions Holding AKBA

# of Institutions

121

Shares Held

54.8M

Call Options Held

291K

Put Options Held

179K

Black Rock Inc. New York, NY

11.6M
Shares

$21.4 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

10.1M
Shares

$18.5 Million
0.0% of portfolio
Satter Management Co., L.P.

5.75M
Shares

$10.6 Million
13.23% of portfolio
Geode Capital Management, LLC Boston, MA

4.75M
Shares

$8.75 Million
0.0% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

3.72M
Shares

$6.84 Million
0.01% of portfolio

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $338M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account